$LWAY

StoneX reiterates Buy on Lifeway Foods stock, $35 target

StoneX reiterated a Buy rating on Lifeway Foods (LWAY) with a $35.00 price target, citing growth opportunities and operational expansion. The company reported 26% revenue growth and record Q2 2026 sales of $66.9 million, but faces margin pressure from rising costs. Other analysts also upgraded LWAY with varying price targets. The stock trades at $22.16, with a Fair Value estimate of $21.68.

Original reporting
Published Oct 12, 2026, 12:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 12:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$LWAY
Bullish
medium confidence
Mentioned
$LWAY
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$LWAYBullishMed
01

Why it matters

The new rating may attract short‑term buying and support price appreciation toward the target.

02

Market read

Analyst upgrade could provide a catalyst for LWAY, with limited broader market effect.

03

What to watch

Potential supply‑chain cost pressures from milk and resin.

Relevance 6/10Novelty 6/10Timing: today

Background

StoneX issued a fresh Buy rating and $35 target for Lifeway Foods, highlighting recent revenue growth and margin challenges.

Company-level read

Ticker impact

$LWAYBullishMedium confidence
Context

StoneX reiterated a Buy rating on Lifeway Foods with a $35 price target, citing 26% revenue growth and margin compression.

Expected impact

likely upward pressure as investors price in the new $35 target

Evidence & confidence

The rating and target are fresh analyst commentary; the stock trades well below the target, suggesting upside potential.

Market effects

Positive outlook may lift other specialty food stocks.

Limited to US consumer‑goods sector.

Minimal global impact.

Counterpoint

Margin compression could offset growth, keeping price muted.

Key entities

  • Lifeway Foods

    US‑listed kefir producer (NASDAQ:LWAY).

  • StoneX

    Research firm providing the rating.

Related articles

$LWAYMed

Lifeway Foods® Delivers Highest Quarterly Net Sales in Company History, Extending Record Growth in Second Quarter 2026

Lifeway Foods, Inc. (LWAY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lifeway Foods® Delivers Highest Quarterly Net Sales in Company History, Extending Record Growth in Second Quarter 2026 $66.9 million in net sales, up 24.1% year-over-year and $3.9 million above the prior quarterly record 27th consecutive quarter of year-over-year net

$ABBVMed

What Does AbbVie (ABBV) 51% DLBCL Risk Reduction Mean For Its Oncology Push?

AbbVie (ABBV) and Genmab reported positive Phase 3 trial results for epcoritamab plus R-CHOP in high-risk diffuse large B-cell lymphoma, showing a 51% reduction in disease progression or death risk. The data suggest potential for front-line treatment, supporting AbbVie's oncology ambitions and revenue diversification. Regulatory filings and approvals will be key next steps.

$PRAXMed

PRAX Initiated Coverage by UBS -- Price Target Announced at $706

UBS initiated coverage on Praxis Precision Medicine (PRAX) with a 'Buy' rating and a $706 price target. The company's current price is $248.24, which is significantly higher than its GF Value of $11.67, indicating a 2027.2% overvaluation. PRAX has a GF Score of 40, reflecting concerns about its financial health and growth potential. The company is a clinical-stage biopharmaceutical firm focusing on central nervous system disorders.

$REGNMed

REGN Upgraded by UBS -- Price Target Raised to $978

UBS upgraded Regeneron Pharmaceuticals (REGN) to 'Buy' with a $978 price target, up 48.18% from $660. GuruFocus values REGN at $925.48, suggesting it's 14.0% undervalued. The company has a GF Score of 87/100, strong financials, and a market cap of $81.99B. Analysts cite growth potential and resilience in its products, like Eylea and Dupixent.